SavedAdd your journal

Journals / Turkish Journal of Hematology / 2009 / Cilt: 26 - Sayı: 2

Tiroid papiller karsinomu için verilen radyoaktif i̇yot tedavisi sonrası akut miyeloid lösemi

Acute myeloid leukemia following radioactive iodine therapy for papillary carcinoma of the thyroid

Jain ANKIT
Premalata CS
Saini KV
Bapsy PP
Sajeevan KV
Tejinder SINGH
Ullas BATRA
Babu GOVİNT
Lokanatha DASAPPA
Suresh ATILLI
Permeshwar R
Pages
97–99
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Thus, all patients with thyroid carcinoma treated with RAI should undergo periodic hematological examinations irrespective of RAI dose.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Radioactive iodine (RAI) therapy plays an important role in the management of thyroid malignancies.
📊
Key Findings & Data:There are very few case reports with doses below 100 mCi causing leukemia.
💡
Conclusion & Impact:Thus, all patients with thyroid carcinoma treated with RAI should undergo periodic hematological examinations irrespective of RAI dose.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Lösemi · miyeloid · akut

Abstract

Radioactive iodine (RAI) therapy plays an important role in the management of thyroid malignancies. Leukemia is a very rare complication of radioactive therapy. There are very few case reports with doses below 100 mCi causing leukemia. We report a case of papillary carcinoma of the thyroid treated with 80 mCi RAI who later developed acute myeloid leukemia. Thus, all patients with thyroid carcinoma treated with RAI should undergo periodic hematological examinations irrespective of RAI dose.

Özet

Radyoaktif iyot (RAİ) tedavisi tiroid malignitelerinin yönetiminde önemli bir rol oynamaktadır. Lösemi, radyoaktif tedavinin çok nadir bir komplikasyonudur. 100mCi altındaki dozların lösemiye neden olduğunu bildiren çok az olgu raporu vardır. Biz, 80 mCi RAİ ile tedavi edilen ve sonrasında akut miyeoid lösemi gelişen bir tiroid papiller karsinom olgusunu bildiriyoruz. Bu nedenle uygulanan RAİ dozuna bakılmaksızın, RAİ ile tedavi gören bütün tiroid karsinomlu hastaların periyodik hematolojik tetkikleri yapılmalıdır.

🔖

Cite This Article

ANKIT, J., CS, P., KV, S., PP, B., KV, S., SINGH, T., BATRA, U., GOVİNT, B., DASAPPA, L., ATILLI, S., R, P. (2009). Tiroid papiller karsinomu için verilen radyoaktif i̇yot tedavisi sonrası akut miyeloid lösemi. Turkish Journal of Hematology, Cilt: 26 - Sayı: 2, 97–99. https://ajindex.com/articles/413389

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Carling T, Udelsman R. Thyroid tumors. In: Devita TV, Hellman S, Rosenberg AS, editors. Cancer: Principles and Practice of Oncology. 7th ed. Philadelphia: Lippincott Williams and Wilkins, 2005: 1502-20
  2. Taylor T, Specker B, Robbins J, et al. Outcome after treatment of high risk papillary and non-Hürthle-cell follicular thyroid carcinoma. Ann Intern Med 1998;129:622
  3. Edmonds CJ, Smith T. The long-term hazards of treatment of thyroid cancer with radioiodine. Br J Radiol 1986;59:45-51
  4. Pochin EE. Leukemia following radioiodine treatment of thyrotoxicosis. Br Med J 1960;2:1545-50
  5. Pochin EE. Prospects from the treatment of thyroid carcinoma with radioiodine. Clin Radiol 1967;18:113-35
  6. Brincker H, Hansen HS, Anderson AP. Induction of leukemia by i-131 treatment of thyroid carcinoma. Br J Cancer 1973;28:232-7
  7. Laurenti L, Salutari P, Sica S, Piccirillo N, Zini G, Zollino M, Leone G. Acute myeloid leukemia after iodine-131 treatment for thyroid disorders. Ann Hematol 1998;76:271-2
  8. Alexander C, Bader JB, Schaefer A, Finke C, Krish CM. Intermediate and long-term side effects of high-dose radioiodine therapy for thyroid carcinoma. J Nucl Med 1998;39:1551-4
  9. Menzel C, Grunwald F, Schomburg A, Palmedo H, Bender H, Späth G, Biersack HJ. “High–dose” radioiodine therapy in advanced differentiated thyroid carcinoma. J Nucl Med 1996;37:1496-503
  10. Petrich T, Widjaja A, Musholt TJ, Hofmann M, Brunkhorst T, Ehrenheim C, Oetting G, Knapp WH. Outcome after radioiodine therapy in 107 patients with differentiated thyroid carcinoma and initial bone metastases: side-effects and influence of age. Eur J Nucl Med 2001;28:203-8
  11. Weinberg RA. The action of oncogenes in the cytoplasm and nucleus. Science 1985;230:770-6
  12. Chow SM. Side effects of high-dose radioactive iodine for ablation or treatment of differentiated thyroid carcinoma. J HK Coll Radiol 2005;8:127-35
  13. Walgraeve D, Verhoef G, Stul M, Cassiman JJ, Mecucci C, Van den Berghe H, Boogaerts M. Chronic myelogenous leukemia after treatment with 131I for thyroid carcinoma. Report of a case and review of the literature. Cancer Genet Cytogenet 1991;55:217-24
  14. Shimon I, Kneller A, Olchovsky D. Chronic myeloid leukaemia following 131I treatment for thyroid carcinoma: a report of two cases and review of the literature. Clin Endocrinol 1995;43:651–4
  15. Kolade VO, Bosinski TJ, Ruffy EL. Acute promyelocytic leukemia after iodine-131 therapy for Graves' disease. Pharmacotherapy 2005;25:1017-2